Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (981-990 of 1,095) with videos related to

Pageof 110
Sort By:
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Journal of Hepatology|May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionKosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Journal of Virology|April 20, 2018
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8<sup>+</sup> T CellsHadi Karimzadeh, Muthamia M Kiraithe, Anna D Kosinska, et al.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
Immunotherapy|February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa studyMelissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.
International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Pageof 110

Showing results (981-990 of 1,095) with videos related to

Sort By:
Pageof 110
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
Journal of Hepatology|May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionKosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Cancer Immunology, Immunotherapy : CII|March 24, 2026
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)Veronica Mollica, Francesco Massari, Kazutoshi Fujita, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Journal of Virology|April 20, 2018
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8<sup>+</sup> T CellsHadi Karimzadeh, Muthamia M Kiraithe, Anna D Kosinska, et al.
JCO Global Oncology|October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 StudyFrancesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology|August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 studyMaria T Bourlon, Luca Galli, Enrique Grande, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 6, 2021
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver DiseaseZobair M Younossi, Janus P Ong, Hirokazu Takahashi, et al.
Immunotherapy|February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa studyMelissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.
International Journal of Cancer|September 7, 2024
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)Chiara Ciccarese, Thomas Büttner, Linda Cerbone, et al.
Pageof 110